GLP-1 Market
LLY $1157.49 ▲ +1.3% NVO $37.53 ▼ -0.0% PFE $27.50 ▲ +0.3% VKTX $28.38 ▼ -3.1% KLRA $10.83 ▼ -0.1% GPCR $27.47 ▼ -0.4% RHHBY $52.55 ▲ +0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

clofutriben

Company
Sparrow Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 7, 2026

Find a Clinical Trial Near Me

See recruiting studies for clofutriben and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07227922

    Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

    Not yet reported Sparrow Pharmaceuticals 16 participants Est. completion 2026-07-01 1 site Stand-alone
    Other conditions: Moderate Renal Impairment
    View official trial listing →
  • Recruiting NCT NCT07296484

    Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

    Not yet reported Sparrow Pharmaceuticals 1500 participants Est. completion 2028-06-30 61 sites Stand-alone
    Type 2 diabetes Other conditions: Cortisol Excess
    View official trial listing →
  • Completed NCT NCT02194491

    A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

    Not yet reported Astellas Pharma Global Development, Inc. 18 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers
    View official trial listing →
  • Terminated NCT NCT02372578

    Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

    Not yet reported Astellas Pharma Global Development, Inc. 115 participants Est. completion 2016-05-20 37 sites Stand-alone
    Other conditions: Painful Diabetic Peripheral Neuropathy (PDPN)
    View official trial listing →
  • Completed NCT NCT05307328

    SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

    Not yet reported Sparrow Pharmaceuticals 26 participants Est. completion 2025-08-01 12 sites Stand-alone
    Other conditions: Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
    View official trial listing →
  • Completed NCT NCT05409027

    A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

    Not yet reported Sparrow Pharmaceuticals 12 participants Est. completion 2024-02-07 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity, Type2Diabetes
    View official trial listing →
  • Completed NCT NCT05436639

    SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Not yet reported Sparrow Pharmaceuticals 30 participants Est. completion 2025-02-18 5 sites Stand-alone
    Other conditions: Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
    View official trial listing →
  • Completed NCT NCT05436652

    A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

    Not yet reported Sparrow Pharmaceuticals 66 participants Est. completion 2025-04-25 10 sites Stand-alone
    Other conditions: Polymyalgia Rheumatica
    View official trial listing →
  • Terminated NCT NCT06281236

    A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

    Not yet reported Sparrow Pharmaceuticals 1 participants Est. completion 2025-04-25 5 sites Stand-alone
    Other conditions: Polymyalgia Rheumatica
    View official trial listing →
  • Completed NCT NCT07226635

    Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone

    Not yet reported Sparrow Pharmaceuticals 16 participants Est. completion 2025-12-16 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: clofutriben, SPI-62, ASP3662

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.